Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast for early oligoarticular psoriatic arthritis
2018-002735-26Phase 4Recruiting
- Sponsor
- Amgen
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Apremilast + background therapy with Placebo + background therapy (2 arms). Primary endpoint: MDA-Joints response. Started Oct 2018; status: recruiting.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2018-002735-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002735-26.